Lytix Biopharma Announces Regulatory Approval by Norwegian and Swedish Authorities to Commence Phase I Clinical Trial of Oncopore(TM) (LTX-315) in Cancer
TROMS, Norway--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency (”Statens legemiddelverk”) and the Swedish Medical Products Agency (”Läkemedelverket”) to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.